2022
92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies
PETTUS J, LIU J, TITIEVSKY L, HAGAN K, LIU T, CHANDARANA K, GAGLIA J, WOLF W, BISPHAM J, CHAPMAN K, FINAN D, SHERR J. 92-OR: Persistence of Impaired Awareness of Hypoglycemia, Severe Hypoglycemic Events, and Suboptimal Glycemic Control Despite Advanced Diabetes Technologies. Diabetes 2022, 71 DOI: 10.2337/db22-92-or.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsRate of severe hypoglycemic eventsAwareness of hypoglycemiaGlycemic controlContinuous glucose monitoringHypoglycemic eventsPrevalence of impaired awareness of hypoglycemiaHybrid closed-loop systemProportion of patientsTarget glycemic controlNational Institute of DiabetesSuboptimal glycemic controlDigestive and Kidney DiseasesT1D Exchange RegistryPatient cohortMedical historyKidney diseaseNon-CGM usersSelf-reported medical historyT1D treatment
2010
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal Of Medicine 2010, 363: 311-320. PMID: 20587585, DOI: 10.1056/nejmoa1002853.Peer-Reviewed Original ResearchConceptsInjection therapy groupPump-therapy groupSensor-augmented pump therapyGlycated hemoglobin levelsHemoglobin levelsType 1 diabetesPump therapyBaseline glycated hemoglobin levelMultiple daily insulin injectionsType 1 diabetes mellitusGlycated haemoglobin targetPrimary end pointProportion of patientsDaily insulin injectionsSignificant weight gainRecombinant insulin analogueHemoglobin targetsInjection therapyDiabetes mellitusSevere hypoglycemiaInsulin injectionsClinical teamInsulin analoguesEnd pointTherapy